Furthermore, using PBMCs from four individual patients with severe COVID-19 and admitted to hospital Intensive Care Units, we demonstrated that in three of four patients, the expression of CXCL10 was increased compared to healthy controls; in all four patients, these levels were reduced to basal levels after treatment with 4-OI (Fig. 4k), indicating that 4-OI was able to reverse the inflammatory response in patients PBMCs ex vivo. The gene discussed is CXCL10; the disease is COVID-19.